TerminatedPhase 2NCT01836549
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Studying Anaplastic astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pediatric Brain Tumor Consortium
- Principal Investigator
- Maryam Fouladi, MDPediatric Brain Tumor Consortium
- Intervention
- imetelstat sodium(drug)
- Enrollment
- 43 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2013 – 2016
Study locations (11)
- Childrens Hospital Los Angeles, Los Angeles, California, United States
- Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Lurie Children's Hospital- Chicago, Chicago, Illinois, United States
- NCI - Pediatric Oncology Branch, Bethesda, Maryland, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Duke Comprehensive Cancer Center, Durham, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
- Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01836549 on ClinicalTrials.govOther trials for Anaplastic astrocytoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07448480Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant GliomasBlokhin's Russian Cancer Research Center
- RECRUITINGEARLY PHASE1NCT06333899Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionNationwide Children's Hospital
- RECRUITINGPHASE1, PHASE2NCT05956821Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of AgeUniversity of Miami
- ACTIVE NOT RECRUITINGPHASE1NCT06614855A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant GliomaJames Markert, MD
- RECRUITINGPHASE2NCT06161974Study of Olutasidenib and Temozolomide in HGGRigel Pharmaceuticals
- RECRUITINGPHASE2NCT05843253Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantNationwide Children's Hospital
- RECRUITINGNCT05839379Targeted Pediatric High-Grade Glioma TherapyNationwide Children's Hospital
- RECRUITINGPHASE2NCT06264388DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaAshish Shah